MS-553 + venetoclax + obinutuzumab

This drug is a **combination therapy** comprising **MS-553**, **venetoclax**, and **obinutuzumab**. - **Venetoclax** is an oral small molecule BCL2 inhibitor that promotes cancer cell death by blocking BCL2, an anti-apoptotic protein predominantly expressed in chronic lymphocytic leukemia (CLL) and other hematological malignancies[3][5]. - **Obinutuzumab** is a glycoengineered type II anti-CD20 monoclonal antibody that binds to and targets CD20 expressed on B-cells, marking them for immune-mediated destruction[2][4][5]. - **MS-553** does not correspond to a widely recognized pharmaceutical, investigational anti-cancer agent, or established code name in hematology/oncology as of the current knowledge cut-off date. No clinical trial or preclinical data specific to "MS-553" in combination with venetoclax and obinutuzumab is published or indexed in recognized medical literature. - **Venetoclax plus obinutuzumab** is FDA-approved for first-line treatment of CLL and small lymphocytic lymphoma, and their mechanism provides a chemotherapy-free, time-limited, highly effective regimen for CLL[3][5]. - The status, pharmacology, or mechanism of **MS-553** in this regimen is undetermined.

Other names

GDC-0199GDC0199GDC 0199ABT-199ABT199ABT 199Gazyvaro